Patents by Inventor Aviv Regev

Aviv Regev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11996168
    Abstract: The present invention relates to genomic informatics and gene-expression profiling. Gene-expression profiles provide complex molecular fingerprints regarding the relative state of a cell or tissue. Similarities in gene-expression profiles between organic states provide molecular taxonomies, classification, and diagnostics. Similarities in gene-expression profiles resulting from various external perturbations reveal functional similarities between these perturbagens, of value in pathway and mechanism-of-action elucidation. Similarities in gene-expression profiles between organic and induced states may identify clinically-effective therapies. Systems and methods herein provide for the measurement of relative gene abundances, including unbiased selection of and construction of probes and targets designed and methods for using known properties of sparsity of measurements to reach gene abundances.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 28, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Aviv Regev, Eric S. Lander, Brian Cleary, Le Cong
  • Patent number: 11981922
    Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 14, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Publication number: 20240154756
    Abstract: Aspects of the present disclosure also allow for a more efficient way to correct or compensate for IQ mismatch in an environment with multiple TX antennas and multiple IQ modulators. In these environments, a received signal is a beamformed signal which is a combination of all TX antennas passing through different channels and may be received in a single RX antenna. Specifically, the RX side may estimate the composite FDRSB for the TXs and signal back a composite FDRSB to allow the TX to use a single filter to compensate for the composite FDRSB. The composite FDRSB may correspond to the equivalent FDRSB received as a sum of the individual FDRSBS of each of the IQ modulators and IQ antennas at a base station.
    Type: Application
    Filed: November 4, 2022
    Publication date: May 9, 2024
    Inventors: Gideon Shlomo Kutz, Ronen Shaked, Aviv Regev
  • Publication number: 20240146579
    Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a downlink message which may include an indication of a precoder applied to one or more downlink signals. The UE may receive the one or more downlink signals using a demodulation reference signal (DMRS) and the precoder, where the one or more downlink signals may be mismatched in gain and phase. The UE may perform an iterative channel estimation procedure to estimate the downlink channel. The UE may then perform a gain and phase mismatch equalization procedure to equalize an estimated gain and phase mismatch of the one or more downlink signals based on the estimated downlink channel and the precoder. The UE may then receive one or more equalized downlink signals in accordance with the gain and phase mismatch equalization procedure.
    Type: Application
    Filed: October 26, 2022
    Publication date: May 2, 2024
    Inventors: Aviv Regev, Ronen Shaked, Yaniv Eistein
  • Publication number: 20240137259
    Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a reference signal from a network entity. The UE may transmit, to the network entity, an estimation of a frequency domain imbalance between an in-phase portion of the reference signal and a quadrature-phase portion of the reference signal based on a precoding matrix associated with transmissions from the network entity and an estimation of one or more channel conditions between the UE and the network entity. The network entity may perform an imbalance compensation operation that balances the in-phase portion and the quadrature-phase portion of the transmission chain based on the estimation of the frequency domain imbalance. The UE may receive, from the network entity, a data transmission based on transmitting the indication of the estimation of the frequency domain imbalance.
    Type: Application
    Filed: October 23, 2022
    Publication date: April 25, 2024
    Inventors: Aviv Regev, Ronen Shaked
  • Patent number: 11963966
    Abstract: Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 23, 2024
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Levi Garraway, Benjamin Izar, Aviv Regev, Orit Rozenblatt-Rosen, Asaf Rotem, Elizabeth Stover, Itay Tirosh
  • Patent number: 11968062
    Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a downlink message which may include an indication of a precoder applied to one or more downlink signals. The UE may receive the one or more downlink signals using a demodulation reference signal (DMRS) and the precoder, where the one or more downlink signals may be mismatched in gain and phase. The UE may perform an iterative channel estimation procedure to estimate the downlink channel. The UE may then perform a gain and phase mismatch equalization procedure to equalize an estimated gain and phase mismatch of the one or more downlink signals based on the estimated downlink channel and the precoder. The UE may then receive one or more equalized downlink signals in accordance with the gain and phase mismatch equalization procedure.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: April 23, 2024
    Assignee: QUALCOMM Incorporated
    Inventors: Aviv Regev, Ronen Shaked, Yaniv Eistein
  • Patent number: 11957695
    Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 16, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20240121639
    Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, an indication of a phase noise power level associated with the network node. The UE may receive, from the network node, a communication without applying phase noise correction associated with the communication based at least in part on the phase noise power level and one or more conditions being satisfied. Numerous other aspects are provided.
    Type: Application
    Filed: September 29, 2022
    Publication date: April 11, 2024
    Inventors: Aviv REGEV, Ronen SHAKED
  • Patent number: 11913075
    Abstract: The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: February 27, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Aviv Regev, Orit Rozenblatt-Rosen, Benjamin Izar, Livnat Jerby, Asaf Rotem
  • Patent number: 11904310
    Abstract: The present invention generally relates to a controlled fluidic device to develop spatially complex environments to enhance the rate of evolution in cell populations. The method further provides an enhanced understanding in the emergence, for example, drug resistance during cancer chemotherapy.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 20, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Anindita Basu, Christopher B. Ford, Aviv Regev, David A. Weitz, Asaf Rotem, Kevin Struhl
  • Patent number: 11897953
    Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 13, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Ayshwarya Subramanian, Orit Rozenblatt-Rosen
  • Publication number: 20240043934
    Abstract: Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from heterogeneity-score a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.
    Type: Application
    Filed: August 22, 2021
    Publication date: February 8, 2024
    Inventors: Aviv Regev, William Hwang, Karthik Jagadeesh, Jimmy Guo, Tyler Jacks, Hannah Hoffman
  • Publication number: 20240039646
    Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, an indication of a non-linearity level associated with transmit antennas of the network node. The UE may selectively perform non-linearity correction for a downlink communication received from the network node based at least in part on the indication of the non-linearity level. Numerous other aspects are described.
    Type: Application
    Filed: July 26, 2022
    Publication date: February 1, 2024
    Inventors: Aviv REGEV, Ronen SHAKED
  • Patent number: 11884717
    Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: January 30, 2024
    Assignees: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. Kuchroo, Chao Wang, Aviv Regev, Karthik Shekhar
  • Publication number: 20240002936
    Abstract: The present disclosure is directed to methods of screening for pathological mechanisms in neurodevelopmental and neuropsychological disorders using brain organoids. The present disclosure is also directed to methods of screening agents using the brain organoids.
    Type: Application
    Filed: November 1, 2021
    Publication date: January 4, 2024
    Inventors: Paola Arlotta, Joshua Z. Levin, Amanda J. Kedaigle, Aviv Regev, Bruna Da Silveira Paulsen, Silvia Velasco, Martina Pigoni
  • Publication number: 20230403051
    Abstract: Certain aspects of the present disclosure provide a method for wireless communications by a network entity. The method may include receiving an indication indicating a subset of one or more precoding matrix vectors associated with an estimated channel between a user equipment (UE) and the network entity. The subset of one or more precoding matrix vectors are part of a precoding matrix. The method may include calculating remaining precoding matrix vectors for the precoding matrix, based on the subset of one or more precoding matrix vectors. The method may include generating the precoding matrix based on the subset of one or more precoding matrix vectors and the remaining precoding matrix vectors. The method may include performing precoding of a downlink transmission based on the precoding matrix.
    Type: Application
    Filed: May 23, 2022
    Publication date: December 14, 2023
    Inventors: Aviv REGEV, Ronen SHAKED
  • Patent number: 11841371
    Abstract: The application relates to methods and systems for proteomics and spatial mapping of biomolecules using a next generation sequencing readout to decipher biomolecular and cellular interaction networks. Specifically, disclosed are antenna networks generated by conjugating DNA antennas to proteins. The antennas carry a unique antenna identifier (UAI) sequence that can provide spatial location of the network, as well as biomolecules by transfer of the UAI to reporter oligonucleotides associated with other antennas and biomolecules. The methods and systems are also applicable to single cells.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: December 12, 2023
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Aviv Regev, Jellert Gaublomme
  • Patent number: 11793787
    Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: October 24, 2023
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20230324371
    Abstract: Compositions and systems comprising a dorsal forebrain organoid having a core comprising less than 25% apoptotic or hypoxic cells and one or more tumor cells in the organoid.
    Type: Application
    Filed: August 12, 2021
    Publication date: October 12, 2023
    Inventors: Paola Arlotta, Mario L. Suva, Aviv Regev, Kwanghun Chung, Vamsi Mangena, Rafaela Sartore